A Phase 1, Two Period Fixed-sequence Crossover Study to Assess the Effects of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Surufatinib in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Itraconazole (Primary) ; Surufatinib (Primary)
Indications Biliary cancer; Neuroendocrine tumours; Solid tumours; Thyroid cancer
Focus Pharmacokinetics
Sponsors Hutchison MediPharma

02 Feb 2021 Status changed from active, no longer recruiting to completed.
07 Nov 2020 Status changed from not yet recruiting to active, no longer recruiting.
06 Jul 2020 Planned End Date changed from 1 Jul 2020 to 1 Dec 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com